Symic Bio starts enrolment in Phase II trial of osteoarthritis drug

Biopharmaceutical firm Symic Bio has started patient enrolment in a Phase II clinical trial (MODIFY2) of its product candidate SB-061 to treat osteoarthritis of the knee.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news